Found: 3
Select item for more details and to access through your institution.
High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy.
- Published in:
- 2019
- By:
- Publication type:
- journal article
The Type II Anti‐CD20 Antibody Obinutuzumab (GA101) Is More Effective Than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model.
- Published in:
- Arthritis & Rheumatology, 2021, v. 73, n. 5, p. 826, doi. 10.1002/art.41608
- By:
- Publication type:
- Article
B cell depletion with anti-CD20 promotes neuroprotection in a BAFF-dependent manner in mice and humans.
- Published in:
- Science Translational Medicine, 2024, v. 16, n. 737, p. 1, doi. 10.1126/scitranslmed.adi0295
- By:
- Publication type:
- Article